EIDX News and Press, Eidos Therapeutics Inc. From 11/18/19

Eidos Therapeutics ( EIDX +13% ) announces positive data from the ongoing open-label extension (OLE) of a Phase 2 study evaluating AG10 in patients with symptomatic transthyretin (TTR) amyloidosis cardiomyopathy (ATTR-CM). The results were presented at the American Heart Association ...

AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular Hospitalization (25.5%) Observed in Exploratory Analysis Were Lower than Rates Observed in Placebo-...

AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular Hospitalization (25.5%) Observed in Exploratory Analysis Were Lower than Rates Observed in Placebo-...

Axonics Modulation Technologies (NASDAQ: AXNX ) initiated with Overweight rating at Piper Jaffray. More news on: Axonics Modulation Technologies, Inc., Homology Medicines, Inc., Sarepta Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Eidos Therapeutics (NASDAQ: EIDX ): Q3 EPS of $0.18 may not be comparable to consensus of -$0.27. More news on: Eidos Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SAN FRANCISCO, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX), a subsidiary of BridgeBio Pharma, Inc. (BridgeBio) (Nasdaq:BBIO), today reported its financial results for the third quarter ended September 30, 2019 and provided an update on the companyȁ...

The $79 million that Vyndaqel contributed to Pfizer 's (NYSE: PFE) third-quarter revenue doesn't mean a whole lot to the pharmaceutical giant . It amounted to a whopping 0.6% of the company's overall revenue. But you can bet that executives at Alnylam Pharmaceuticals (NASDAQ: ALNY) , Ak...

Original Post Editor's Note : The summary bullets for this article were chosen by Seeking Read more ...

Eidos Therapeutics (NASDAQ: EIDX)  has escaped being swallowed up by its parent company,  BridgeBio Pharma (NASDAQ: BBIO) . BridgeBio owned 54.5% of Eidos when the latter went public in June 2018; that number grew to 61% by the end of 2018 and has reached 66% today. Thus, the two ...

Agreement Not Reached Between BridgeBio Pharma and Special Committee of Eidos Therapeutics Independent Directors; BridgeBio No Longer Pursuing Acquisition BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced today that...